Not yet recruiting NCT07355478
Asia Myelodysplastic Syndrome (MDS) Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Prescribed treatments for myelodysplastic syndromes (MDS).
- Who it may be relevant to
- Registry conditions: Myelodysplastic Syndromes (MDS). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Singapore, South Korea, Taiwan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
Interventions
- Drug Prescribed treatments for myelodysplastic syndromes (MDS)
According to the product label
Primary outcome measures
- Participant age [Time frame: Baseline]
- Participant sex [Time frame: Baseline]
- Participant race [Time frame: Baseline]
- Participant weight [Time frame: Baseline]
- Participant height [Time frame: Baseline]
- Participant body mass index (BMI) [Time frame: Baseline]
- Participant smoking status [Time frame: Baseline]
- Participant drinking status [Time frame: Baseline]
- Family history of MDS or other hematopoietic cancers [Time frame: Baseline]
- Participant myelodysplastic syndromes diagnosis information [Time frame: Baseline]
Secondary outcome measures (12)
- Initial treatment received following diagnosis [Time frame: Baseline]
- Prior treatments and concomitant medications received [Time frame: Baseline]
- Subsequent treatments received [Time frame: Up to 2-years]
- Time from diagnosis to treatment initiation [Time frame: Baseline]
- Treatment duration [Time frame: Up to 2-years]
- Real-world overall survival (rwOS) [Time frame: Baseline and up to 2-years]
- Time to disease-risk progression (per IPSS-R) [Time frame: Baseline and up to 2-years]
- Time to acute myeloid leukemia (AML) progression [Time frame: Baseline and up to 2-years]
- Time to iron overload [Time frame: Baseline and up to 2-years]
- Overall response rate (ORR) [Time frame: Baseline and up to 2-years]
- Duration of response (DOR) [Time frame: Baseline and up to 2-years]
- Real-world relapse-free survival (rwRFS) [Time frame: Baseline and up to 2-years]
Eligibility criteria
Inclusion criteria
Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:
- Aged at least 18 years at initial diagnosis of MDS
- Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
- Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate
Inclusion criteria for the prospective enrolment of MDS participants:
- Aged at least 18 years at initial diagnosis of MDS; and
- Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
- Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate
Exclusion criteria
- None
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Singapore · 1 center
- Local Institution - 0003 — Singapore
South Korea · 1 center
- Local Institution - 002 — Seoul
Taiwan · 1 center
- Local Institution - 0001 — Taipei
Identifiers
NCT: NCT07355478 · CA056-1131